跳至主要内容
临床试验/NCT07257887
NCT07257887招募中不适用

Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis

ENIKAM d.o.o.4 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2025年11月19日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
90
试验地点
4
主要终点
Probing depth

研究概览

简要总结

Periodontitis is a chronic, irreversible inflammatory disease affecting the supporting structures of the teeth. It is most commonly caused by bacteria in dental plaque, also known as biofilm. The disease typically begins as gingivitis, a reversible inflammation of the gums resulting from plaque accumulation. Without appropriate intervention-such as maintaining proper oral hygiene and removing plaque-gingivitis can progress to periodontitis, leading to the loss of clinical attachment, alveolar bone resorption, and eventually tooth loss.

Early diagnosis and regular treatment of periodontal disease are essential to prevent disease progression. The treatment of periodontitis is primarily causal and involves the mechanical removal of plaque. Initial therapy is non-surgical, consisting of scaling and root planing, and may be followed by surgical procedures if required. In addition to mechanical cleaning, increasing attention has been given to adjunctive, non-invasive therapies such as mouth rinses or oral solutions containing chlorhexidine or hydrogen peroxide. These agents have antimicrobial properties, help reduce plaque accumulation, and support tissue healing.

Hydrogen peroxide mouth rinses have been used for more than a century as an adjunct to mechanical plaque removal and for the prevention or management of oral infections. However, despite their long history of use, clinical studies evaluating hydrogen peroxide-based mouth rinses remain limited and heterogeneous in design, which makes it difficult to compare findings across studies.

The objective of this post-marketing clinical study is to generate additional data on the safety and efficacy of a hydrogen peroxide mouth rinse as an adjunctive therapy in the treatment of periodontitis. The study will evaluate two hydrogen peroxide concentrations: a 1.5% solution (Oroxid® sensitive) and a 3% solution (Oroxid® forte).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Systemically healthy participants aged 18 years or older.
  • Generalized periodontitis, Stage III, Grade B.
  • Presence of three or more periodontal pockets deeper than 5 mm.
  • At least 16 natural teeth (excluding wisdom teeth).
  • Ability to comply with oral hygiene instructions following the intervention.
  • Signed informed consent form after being fully informed about the study.

排除标准

  • Periodontal treatment within the past six months.
  • Dental procedures (surgery, professional cleaning, scaling and root planing, laser therapy, piezotome) within the past six months.
  • Periodontitis, Stage IV.
  • Use of mouth rinses or oral gels within the past month.
  • Use of antibiotic therapy within the past three months.
  • Ongoing therapy with antihypertensives, antilipemics, antiarrhythmics, or other cardiovascular medications.
  • Systemic diseases such as diabetes, HIV/AIDS, liver diseases, chronic kidney disease, tuberculosis, and autoimmune disorders (e.g., lupus, scleroderma, Crohn's disease).
  • History of cardiovascular diseases, including acute myocardial infarction, angina pectoris, heart failure, atrial fibrillation, atrioventricular block, peripheral artery disease, or stroke.
  • Therapy with immunosuppressive agents.
  • Allergy to any ingredients of the study products.
  • Pregnant or breastfeeding women.

结局指标

主要结局

Probing depth

时间窗: Baseline and Week 12

Mean change in probing depth (measured in millimeters) from baseline to Week 12, comparing the two active treatment groups (OROXID® forte and OROXID® sensitive) with the control group. Probing Depth is the measurement of the distance from the gingival margin to the bottom of the periodontal pocket using a periodontal probe. Values typically range from 1-3 mm (healthy) to ≥5 mm (indicative of periodontal disease), with deeper pockets reflecting more severe attachment loss.

Bleeding on Probing (BOP)

时间窗: Baseline and Week 12

Difference in the presence of bleeding on probing (BOP) between the two active treatment groups and the control group after 12 weeks of treatment. BOP evaluates gingival inflammation by recording the presence/absence of bleeding within 30 seconds after gentle periodontal probing, serving as a key diagnostic indicator of active periodontal disease.

次要结局

  • Gingival Index (GI)(Baseline and Week 12)
  • Plaque Index (PI)(Baseline and Week 12)
  • Adverse events(Throughout the 12-week study period)
  • Rate of infection(Up to week 12)

研究者

发起方
ENIKAM d.o.o.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验